Filing Flows › RxSight (RXST) › Q2 2025
RxSight (RXST) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
RxSight (RXST) reported revenue of $33.6M for the second quarter 2025 (Q2 2025), -4% from a year earlier and -11% from the quarter before. Operating margin was -41.6%, net loss $11.8M (35.0% of revenue).
RxSight, Q2 2025: revenue $33.6M (-4% year over year), operating margin -41.6%, net loss $11.8M, operating cash flow −$4.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $33.6M | -11% | -4% |
| Operating profit | −$14.0M | — | — |
| Net earnings | −$11.8M | — | — |
| Operating cash flow | −$4.4M | — | — |
What changed
Revenue was $33.6M in Q2 2025, down 4% year over year and down 11% from the previous quarter. Rxlal was the largest line at 80% of revenue. LDD lost $5.1M year over year (down 50%), 404% of the total change.
Gross margin was 74.9%, up 5.4 points from a year earlier. Operating costs exceeded revenue by $14.0M, an operating margin of -41.6%. Operating expenses grew 20% against a revenue fall of 4%. The fastest-growing cost line was Research & development (+23%). The quarter ended with a net loss of $11.8M, wider than the previous quarter's $8.2M loss.
Operating cash flow was −$4.4M. Non-cash charges added back $785K of depreciation and amortization and $8.5M of share-based compensation. Working capital and other items used $1.9M. Capital expenditures of $1.5M exceeded it, leaving free cash flow of −$5.9M.
Questions
What was RxSight's revenue in the second quarter 2025?
RxSight (RXST) reported revenue of $33.6M for the second quarter 2025 (Q2 2025), -4% from a year earlier and -11% from the quarter before.
Was RxSight profitable in the second quarter 2025?
Operating loss was $14.0M (-41.6% of revenue) and net loss $11.8M.
Source: RxSight 10-Q on SEC EDGAR.